Colorectal Cancer

The colorectal cancer (CRC) is the second leading cause of death by cancer in the Western world. Combined, in both sexes, colorectal cancer is the third-most common cancer and accounts for 9.7% of all cancers excluding non-melanoma skin cancer.

The majority of patients with sporadic cancer are >50 years of age, with 75% of patients with rectal cancer and 80% of patients with colon cancer patients being ≥60 years of age at the time of diagnosis.
Based on current incidence and mortality rates as well as on projected demographic changes in the world population for the coming decades, the World Health Organization (WHO) estimates an increase of 77% in the number of newly diagnosed CRC cases and an increase of 80% in deaths from CRC by 2030. Most of the additional incidence and mortality would occur in the world’s less developed regions. This estimation could be higher if developing countries continue with an increasingly Westernized lifestyle

The prevalence of the disease is higher in more industrialized countries, such as the USA and Western Europe, being lower in Africa or South America.
Over 70% of CRC cases are sporadic and thus related to lifestyle. Despite being one of the most common cancers, CRC is also one that could benefit most from prevention through primary and secondary prevention strategies, and it is estimated that between 66% and 75% of CRC cases could be avoided with a healthy lifestyle.

The known risk factors for CRC are as follows: a diet low in fruit and vegetables, excessive intake of red meat and saturated fat, alcohol intake, a sedentary lifestyle, tobacco and being overweight. However, the main risk factor is age. From 50 onwards, CRC is much more frequent, and the incidence increases exponentially with age.
However various techniques are available to detect CRC in its early stages or as precursor lesions, thereby preventing aggressive treatment. Moreover,  Unlike screening programs for breast and prostate cancers, not only has CRC screening reduced mortality from colon cancer and detected early CRC, it has also decreased the incidence of CRC through detection and removal of pre-cancerous lesions.

Surgery is the mainstay curative treatment for patients with non-metastasized colorectal cancer. However, outcome is strongly related to the quality of surgery, the quality of pre-operative staging and treatment selection. Chemotherapy remains the cornerstone of systemic treatment today, but several new targeted drugs have emerged in this filed in the last decade, improving the management of metastatic disease. The recent advances in molecular biology and the genetic classification of CRC are essential to individualize these therapies and will be basic for improving the treatment in the next years.

Colorectal Cancer Studies


Colorectal Cancer Studies


There are several studies available, here are some of the ones you can find:
Status Study Conditions Interventions Locations
Recruiting Metastatic Colorectal Cancer Database Metastatic Colorectal Cancer Other: Metastatic Colorectal Cancer Database Methodology, Biostatistics and Data Management
Dijon, France
Recruiting  Dabrafenib + Trametinib + PDR001 In Colorectal Cancer Metastatic Colorectal Cancer
  • Drug: Dabrafenib
    Drug: Trametinib
    Drug: PDR001
Massachusetts General Hosital Cancer Center
Boston, Massachusetts, United States
Dana Farber Cancer Institite
Boston, Massachusetts, United States
Recruiting Study of TAS-102 Plus Radiation Therapy for the Treatment of the Liver in Patients With Hepatic Metastases From Colorectal Cancer Colorectal Cancer
  • Drug: TAS-102;
  • Radiation: Photon SBRT
Massachusetts General Hospital
Boston, Massachusetts, United States
Unknown Participation in Competing Strategies for Colorectal Cancer Screening – a Randomized Health Services Study Within the National Screening Program in Poland Colorectal Cancer Other: Offering a choice for colorectal cancer screening;Other: Offering an alternative colorectal cancer screening method Maria Sklodowska-Curie Institute – Oncology Center
Warsaw, Poland
Recruiting Colorectal Cancer Awareness in Turkey Colorectal Cancer Other: Survey Istanbul Training and Research Hospital
Istanbul, Turkey
Not yet recruiting Lifestyle Intervention Among Participants of the French Colorectal Cancer Screening Program Colorectal Cancer Behavioral: Diet and lifestyle advice following a positive FIT test and diagnostic colonoscopy. International Agency for Research on Cancer
Lyon, Rhone, France
Completed Does Knowing One’s Estimated Colorectal Cancer Risk Influence Screening Behavior? Colorectal Cancer
  • Behavioral: Risk Assessment (CCRAT);
  • Behavioral: Usual Care (UC)
Stanford University School of Medicine
Palo Alto, California, United States
Recruiting  DC Vaccine in Colorectal Cancer Colorectal Cancer
  • Biological: DC vaccine
  • University of Pennsylvania
    Philadelphia, Pennsylvania, United States

New Breathe


New Breathe




Call us now if you are in a medical emergency need, we will reply swiftly and provide you with a medical aid.

2021 © New Breathe. Powered with by Goweb Agency.

2021 © New Breath. Powered with by Goweb Agency.